Claris Lifesciences gets nod for new plant; stock rallies
“This will help in enhancing capacities to grow in the regulated markets, especially the European Union,” the company said.
By ET Online |
MUMBAI: Shares of Claris Lifesciences spiked as the company got MHRA approval for its newly commissioned plant.
The stock rallied over 4% in intraday trade.
“This will help in enhancing capacities to grow in the regulated markets, especially the European Union,” the company said in a press release.
This is the first regulatory inspection and compliance approval conducted by MHRA-UK in line with the EU GMP regulations for the new plant. This approval is for the terminally sterilized products presented in glass ampoules manufactured in Line 1 of the plant.
The company plans to “install another line in this new plant which will be ready for commercial production by end of this year,” the release said.
The stock rallied over 4% in intraday trade.
“This will help in enhancing capacities to grow in the regulated markets, especially the European Union,” the company said in a press release.
This is the first regulatory inspection and compliance approval conducted by MHRA-UK in line with the EU GMP regulations for the new plant. This approval is for the terminally sterilized products presented in glass ampoules manufactured in Line 1 of the plant.
The company plans to “install another line in this new plant which will be ready for commercial production by end of this year,” the release said.
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
Related Articles
Claris Lifesciences shares to delist on March 22ADVERTISEMENT
